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Losing the decisive virus-specific functions of both CD41 and CD81 T lymphocytes in the first weeks after immunodefi-
ciency virus infection ultimately leads to AIDS. The SIV/rhesus monkey model for AIDS was used to demonstrate that a
4-week chemotherapeutic reduction of viral load during acute SIV infection of macaques allowed the development of a
competent immune response able to control virus replication after discontinuation of treatment in two of five monkeys.
Increasing SIV-specific CD41 T-helper-cell proliferation was found in all macaques several weeks after treatment, indepen-
dent of their viral load. However, only macaques with low viral loads showed persistent T-cell reactivity of lymph node cells.
In contrast to animals with higher viral loads, T-helper-cell counts and memory T-helper cells did not decline in the two
macaques controlling viral replication. Lymphocyte apoptosis was consistently low in all treated macaques. In contrast, high
CD81 lymphocyte death but only slightly increased CD41 lymphocyte apoptosis were observed during the first weeks after
infection in untreated control animals, indicating that early apoptotic death of virus-specific CTL could be an important factor
for disease development. Antiretroviral treatment early after infection obviously retained virus-specific and competent T
lymphocytes, whereby a virus-specific immune response could develop in two animals able to control the viral replication
after cessation of treatment. © 2001 Academic Press
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HIV infection usually leads to progressive immuno-
pathogenesis in most individuals, subsequently resulting
in the breakdown of the immune system. There is strong
evidence that the main damage to the immune system
occurs in the first days or weeks after infection, leading
to an impaired immune response against the virus (Des-
rosiers, 1999; Soudeyns et al., 1999). The loss of function
in the CD41 T-helper-cell compartment is one major step
in the weakening of the immune system. The early dys-
function of CD41 T-helper lymphocytes has long been
nown in HIV-infected humans (Clerici et al., 1989) and
SIV-infected macaques (Voss et al., 1992; Dittmer et al.,
1994). Recently, this old observation came into focus
again, when vigorous HIV-1-specific CD41 T-cell re-
ponses were found to be associated with control of
iremia in long-term nonprogressors (Rosenberg et al.,
997; Rosenberg and Walker, 1998; Pontesilli et al., 1999).
n contrast, individuals progressing to AIDS show low or
ven no proliferative activity. CD41 T cells, on the one
1 To whom correspondence and reprint requests should be ad-
ressed at Deutsches Primatenzentrum, Department of Virology andmmunology, Kellnerweg 4, Go¨ttingen D-37077, Germany. Fax: 149 551
3851184. E-mail: mispri@www.dpz.gwdg.de.
221hand, are the primary targets for virus replication; on the
other hand, they play a central role in the development of
an adequate immune response. Virus-specific CD41 T
lymphocytes become activated early after viral infection
and mediate decisive help for the development of anti-
body responses and CTL through the release of specific
cytokines and chemokines. Moreover, they activate den-
dritic cells to mount higher costimulatory activity re-
quired for the activation of specific CTL (Ridge et al.,
1998). Losing the decisive virus-specific functions of T-
helper cells and CTL in the first days after HIV infection
ultimately leads to immunodeficiency and AIDS.
Successful antiretroviral therapy (ART) of HIV-infected
patients usually results in the suppression of virus rep-
lication below the limits of detection by currently avail-
able assays. Treatment with ART reconstitutes the CD41
cell counts and might lead to recovery of CD41 cell
function (Autran et al., 1997; Pakker et al., 1998; Carcelain
t al., 1999). Although the thymus function declines with
ge, substantial production of naı¨ve T cells is maintained
nto late adulthood, and the adult thymus of HIV patients
reated with ART can contribute to immune reconstitution
Douek et al., 1998). It is questionable, however, whether
estoration of virus-specific CD41 T-cell reactivity can beachieved with ART administered in advanced stages of
the disease, when most antiviral T-cell clones might have
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222 SPRING ET AL.already been destroyed by the infection (Connors et al.,
997; Autran et al., 1999). This is a general problem in
IV patients treated late during infection. In most of
hese individuals virus replication increases again after
nterruption of treatment and, as a consequence, these
atients eventually have to be on ART lifelong. Thus,
lements of the T-cell repertoire lost during acute HIV or
IV infection may be difficult to replace.
It has therefore to be evaluated whether early reduc-
ion of viral load by ART could save virus-specific effector
lymphocytes from death and/or loss of function. We
nvestigated in the rhesus macaque model for AIDS
hether the reduction of acute viral load by antiretroviral
herapy alone can induce a competent immune response
hat can control the virus replication after discontinued
reatment. We evaluated in detail the virus-specific T-
elper-cell reactivity and the lymphocyte death in in-
ected and treated macaques. We demonstrated that
hort-term ART early after SIV infection of five macaques
s beneficial for the development of an immune response
gainst SIV and leads to continued low levels of virus
eplication in two animals and reduced virus replication
n one other macaque. Treated animals exhibited re-
uced CD81 lymphocyte apoptosis early after infection
compared to that of untreated macaques. Virus-specific
T-cell-proliferative responses were detected in all ani-
mals, but only the three macaques with the lowest viral
load showed persistent T-cell reactivity of lymph node
FIG. 1. Cell-associated viral load in rhesus macaques treated with P
isolated from the monkey PBMC by a limiting dilution coculture techni
number of infectious cells per 1 3 106 PBMC. The limit of detection of
f PMPA treatment is indicated by two vertical lines. Each monkey is id
uthanized at Weeks 53 and 81 after the infection, when the first signcells. Our data underscore the importance of functional
T-helper cells and low CD81 lymphocyte apoptosis forthe generation of an effective virus-specific immune re-
sponse.
RESULTS
After cessation of PMPA treatment the viral load
remained low or rebounded to different levels in
SIV-infected macaques
Infection of macaques with SIVmac239 generally re-
sults in high virus replication after only 1 week of infec-
tion. Among more than 20 untreated rhesus macaques
infected with SIVmac239 at the German Primate Center
during the last few years, all had sustained viral loads
until their death. To control for the effect of an early
antiretroviral treatment in SIVmac239-infected ma-
caques, we determined the kinetics of viral replication
during and after chemotherapy by measuring the cell-
associated viral load in blood and the amount of free viral
RNA copies in plasma samples. At 1 week after infection
all animals exhibited a high cell-associated viral load
and high numbers of free viral RNA copies in plasma
(Figs. 1 and 2). Therefore, it is expected that after 7 days
virus is distributed to every compartment of the lymphoid
system (Stahl-Hennig et al., 1999). After 4 weeks of PMPA
treatment the cell-associated viral loads decreased in all
animals by approximately 3 orders of magnitude. Four of
the five macaques had cell-associated viral loads below
one infectious cell per 106 PBMC. After cessation of
r 4 weeks, starting 1 week after infection with SIVmac239. Virus was
d the endpoint was determined. The viral load was expressed as the
say (0.3 cells per 106 PBMC) is indicated by a broken line. The period
by a four-digit number. The animals Mm9043 and Mm9027 had to be
munodeficiency emerged.MPA fo
que an
the astreatment the animals could be divided into two groups.
Two animals (Mm9025 and Mm9045) maintained low-to-
lf
rials an
tificatio
223IMMUNE RESPONSE OF SIV-INFECTED MACAQUES AFTER ARTundetectable numbers of infected cells, whereas in three
macaques (Mm9027, Mm9040, and Mm9043) median to
high levels were reached again.
To compare virus replication in the periphery and the
secondary lymphoid tissues of the macaques, we deter-
mined the cell-associated viral load of lymph node lym-
phocytes of the macaques after 52 weeks of infection
(Table 1). Although the viral load of all animals was
higher in lymph node cells than in PBMC, the lower viral
load of two animals (Mm9025, Mm9045) was confirmed.
We also determined the number of infected cells in the
lymph node sections by in situ hybridization with radio-
abeled antisense RNA probes (Table 1). Only few in-
FIG. 2. Plasma viremia in rhesus macaques treated with PMPA for 4 w
copies per microliter of plasma was calculated as described under Mate
ml of plasma, as indicated by the broken line. Treatment period and iden
TABLE 1
Viral Load and Proliferative Response of Axillar Lymph Node Cells
at 52 Weeks after Infection
Animals
Virus
RNA-positive
cellsa (per mm2)
Cell-associated
viral load
T-cell
proliferation
(SI)b
Mm9025 0.08 0.33c 34
Mm9027 0.74 1024 0.7
Mm9040 0.48 258 95
Mm9043 5.13 2048 1.1
Mm9045 0.11 128 23
a Numbers are median values of four sections from each animal.
b SI, stimulation index, SI . 3 were considered positive in the
lymphoproliferative assay.
c Number of infectious cells per 106 lymph node cells; the limit of
detection in this assay is 0.33 cells per 106 lymphocytes.ected cells per mm2 of the section were seen in the
lymph nodes of the two animals with low peripheral viral
load (Mm9025, Mm9045). Five- to sevenfold more posi-
tive cells were detected in two of the other macaques
(Mm9027, Mm9040). In contrast, over 50-fold more cells
were observed in the lymph node of Mm9043, which had
to be euthanized at 53 weeks after infection with AIDS-
like disease, indicating a lack of viral containment.
During and after treatment, the kinetics of the free viral
RNA copies in plasma samples of the monkeys was
similar to the cell-associated viral load (Fig. 2). After
withdrawal of PMPA the amount of viral RNA increased in
all macaques. After this initial increase, the two ma-
caques with the lowest cellular viral load also developed
low-to-undetectable viral RNA loads. In contrast, the
other three animals showed median-to-high copy num-
bers of SIV RNA in their plasma after treatment. Ma-
caques Mm9043 and Mm9027, with the highest viral
loads, had to be euthanized at 53 and 81 weeks after
infection with overt clinical symptoms typical for AIDS-
related disease, i.e., progressive lymphadenopathy,
splenomegaly, severe thrombocytopenia, diarrhea, and
opportunistic infections. The other three animals exhib-
ited no signs of immune impairment.
Absolute number of T-helper cells and memory
T-helper cells
To analyze the CD41 cell pool in the animals, we
determined the absolute numbers of T-helper cells per
starting 1 week after infection with SIVmac239. The number of viral RNA
d Methods. The detection limit of the assay was 40 RNA equivalents per
n of monkeys are as described in the legend to Fig. 1.eeks,microliter of blood (Fig. 3). In comparison with preinfec-
tion values, the number of T-helper cells was increased
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224 SPRING ET AL.at the end of therapy in all monkeys. In the three ma-
caques with higher viral load (Mm9027, Mm9040, and
Mm9043) T-cell counts fell below preinfection values
after treatment, whereas counts remained stable in the
two animals retaining low viral titers. Similarly, the CD4/
CD8 ratio remained at a constant level after treatment in
the two animals with lower virus load. In Mm9043 it
decreased severely and in Mm9027 and Mm9040, mod-
erately, after withdrawal of PMPA (data not shown).
We examined CD29 surface expression on lympho-
cytes as an early marker that provides additional infor-
mation on the composition of the T-cell population (Fig.
4). CD29 is expressed on lymphocytes with a memory
phenotype (Leblond et al., 2000). Based on the expres-
ion density of CD29, two subpopulations of CD41 T
cells could be detected. We only measured the CD41 T
ells with higher CD29 expression, since these
D29bright1 lymphocytes are reduced after HIV or SIV
nfection (Schnittman et al., 1990; Mattapallil et al., 1999;
Sopper et al., 2000; Leblond et al., 2000). The two ani-
als with lower virus load maintained the preinfection
evel of memory T-helper cells after treatment, whereas
D29bright1 cells were decreased in the remaining three
macaques.
Beneficial effect of PMPA treatment on the
development of a cellular immune response
FIG. 3. Number of T-helper cells in the peripheral blood of rhesus m
IVmac239. The absolute numbers of T-helper cells per microliter of bl
cytometry and the absolute number of lymphocytes was obtained by a
or three separate individual measurements collected over 6 weeks and
(SD 5 s 3 n 2 1) are as follows: Mm9025, 350; Mm9027, 300; Mm90
identification of monkeys are as described in the legend to Fig. 1.Virus-specific proliferating T cells are a prerequisite
for the development of effective virus-specific antibodiesand adequate CTL responses capable of controlling viral
replication. In more than 50 untreated SIV-infected ani-
mals, we could never detect any SIV-specific proliferative
activity with our assay (Dittmer and Hunsmann, 1997). To
assess whether the PMPA-induced reduction of viral
loads had a beneficial effect on the T-helper-cell activity,
we determined the SIV-specific lymphoproliferation of
the animals (Fig. 5). T-cell responses were below spe-
cific values in all monkeys during treatment. We first
detected SIV-specific T-helper-cell activity in one ma-
caque (Mm9045) with low viral load, 4 weeks after dis-
continuation of chemotherapy. In the other four animals a
virus-specific proliferation was detectable by either
Week 32 or Week 36 after infection. Interestingly, SIV-
specific proliferation was also detectable several times
in animals with high viral load and decreasing T-helper-
cell counts (i.e., in animals Mm9043 and Mm9027). At 52
weeks after infection all animals were negative for a
T-helper-cell response in the peripheral blood. However,
we still could detect high proliferative activity in lymph
node cells of the two monkeys with low virus loads
(Mm9025 and Mm9045) and one animal (Mm9040) with
moderate virus load, but not in those (Mm9027 and
Mm9043) with highest virus loads (Table 1). Proliferation
was again detectable in the peripheral blood of the
animals Mm9025 and Mm9045 after 52 weeks.
We also examined the proliferative activity of PBMC
s treated with PMPA for 4 weeks, starting 1 week after infection with
re calculated from the percentage CD31CD41 cells measured by flow
ed white blood cell counting. The prevalue was determined from four
an value was calculated. The standard deviations of the mean values
; Mm9043, 309; Mm9045, 207. The period of PMPA treatment and theacaque
ood we
utomat
the meagainst the recall antigen KLH (keyhole limpet hemocya-
nine) at several time points after infection. In untreated
ean v
M nt and
225IMMUNE RESPONSE OF SIV-INFECTED MACAQUES AFTER ARTSIV-infected animals the proliferation against KLH is lost
early after infection (Dittmer et al., 1994). In contrast, we
detected KLH-specific proliferating cells in all treated
animals in parallel with the proliferative responses
against viral antigen (data not shown).
FIG. 4. Number of memory T-helper cells in the peripheral blood of rh
with SIVmac239. The number of CD31CD41CD29bright1 lymphocytes pe
in combination with three-color flow cytometry. The prevalue was dete
and the mean value was calculated. The standard deviations of the m
m9040, 43; Mm9043, 103; Mm9045, 63. The period of PMPA treatme
FIG. 5. SIV-specific proliferative responses of rhesus macaques trea
Stimulation indices (SI) of the five animals were calculated as described
(data not shown), SI . 3 were considered positive, as indicated by the horizo
The identification of monkeys is as described in the legend to Fig. 1.Detection of apoptotic lymphocytes in the peripheral
blood of the macaques
Lymphocyte apoptosis is considered to play a major
role in early lymphocyte dysfunction after infection with
acaques treated with PMPA for 4 weeks, starting 1 week after infection
liter of blood was determined by automated white blood cell counting
from three separate individual measurements collected over 6 weeks
alues (SD 5 s 3 n 2 1) are as follows: Mm9025, 103; Mm9027, 85;
the identification of monkeys are as described in the legend to Fig. 1.
th PMPA for 4 weeks, starting 1 week after infection with SIVmac239.
Materials and Methods. According to three preinfection measurementsesus m
r micro
rminedted wi
underntal line. The period of PMPA treatment is indicated by vertical lines.
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226 SPRING ET AL.immunodeficiency viruses. To evaluate the extent of cell
death occurring in the lymphocyte population of the
PMPA-treated animals, we determined the apoptosis in
CD41 and CD81 cells freshly isolated from the peripheral
blood of the macaques at several time points after infec-
tion. To compare the cell death in the treated animals
with that in SIVmac239-infected untreated macaques, we
also analyzed the T-cell apoptosis of four animals with
progressing disease.
An example of the analyses of one representative
animal for each group is shown in Fig. 6. At 4 weeks after
infection the rate of lymphocyte apoptosis was at base-
line levels in the PMPA-treated monkey Mm9025. In con-
trast, apoptosis increased slightly in CD41 lymphocytes
but more pronounced in the CD81 lymphocyte compart-
ment of the untreated monkey Mm1907.
To investigate the kinetics of lymphocyte apoptosis, an
analysis over time was performed (Table 2). In both CD41
and CD81 lymphocytes of the PMPA-treated monkeys,
he level of apoptosis remained constantly low during
nfection. In contrast, all untreated SIV-infected control
acaques exhibited increased apoptosis in the CD81
lymphocyte population after infection. It was calculated
that, at time points 2, 4, 8, and 12 weeks after infection,
the percentages of CD81 lymphocytes are significantly
higher (P , 0.01) in the untreated animals than in the
treated macaques. Interestingly, CD81 apoptosis peaked
early after the infection and decreased again thereafter.
A slight increase of CD41 lymphocyte apoptosis was
detected in two untreated macaques, but was below the
cutoff, defined as twice the preinfection value.
DISCUSSION
Our experiment revealed that reduction of viral load by
an antiretroviral therapy with PMPA, starting early after
SIV-infection of rhesus macaques, can influence the fur-
ther viral replication in the animals. In four of five ma-
caques a beneficial effect was observed after cessation
of the treatment. In two animals (Mm9025 and Mm9045)
virus replication remained low, with levels around the
detection limit for over 16 months after treatment. Thus,
in those animals a long-term nonprogressor status was
induced. In another two animals (Mm9027 and Mm9040)
virus replication increased only slowly after treatment.
Obviously, the initial reduction in viral replication led to
the generation of virus-specific immune responses, and
to various degrees of control over viral replication. Sev-
eral weeks after withdrawal of therapy, T-helper-cell pro-
liferation could be detected in all animals independently
of high or low viral replication. Similar results confirming
our observations were previously published by other
groups (Rosenwirth et al., 2000; Lifson et al., 2000; Mori
t al., 2000). However, we raised additional data on the
xtent of T-cell activation and apoptosis. PMPA treatment
rotected monkeys against CD81 lymphocyte death,which was prominent in untreated animals. Additionally,
we detected higher numbers of memory T-helper cells in
the peripheral blood of the two macaques successfully
controlling viral replication over a long period of time.
Virus-specific CTL play an important role in containing
immunodeficiency virus replication (Schmitz et al., 1999).
HIV-specific CTL were previously documented early after
infection, before a neutralizing antibody response is de-
monstrable (Koup et al., 1994; Borrow et al., 1994). Loss
of such lymphocytes during acute infection is detrimental
for the development of an antiviral immune response.
Apoptosis was reported to be a major cause for T-
lymphocyte depletion after infection with immunodefi-
ciency viruses. In several studies lymphocyte apoptosis
was investigated after in vitro culture of lymphocytes
(e.g., Gougeon et al., 1996; Herbein et al., 1998a; Rein-
erger et al., 1999; Grelli et al., 2000; Iida et al., 2000).
Increased rates of CD81 T-cell death after HIV infection
of PBMC in vitro were reported to be mediated by mac-
rophages through interaction of HIV gp120 with chemo-
kine receptor CXCR4 (Herbein et al., 1998b). However, a
kinetic study of direct ex vivo analysis of lymphocyte
apoptosis in rhesus macaques was not previously per-
formed. Our data indicate slightly increased death of
CD41 lymphocytes and prominent CD81 lymphocyte
death in untreated, but not in the PMPA-treated, mon-
keys.
After a fraction of virus-specific T cells was depleted
by virus-induced apoptosis in the untreated monkeys, no
adequate immune response could be mounted to control
virus replication. Recently, the induction of CTL apopto-
sis by SIVmac-infected cells was described as a mech-
anism by which the virus could escape immune control
in wild-type infected animals but not in animals infected
with nef-defective SIVmac (Xu et al., 1997, 1999). These
uthors reported that virus-specific CTL can be killed by
irus-infected T cells through NEF-induced FasL expres-
ion on their surface, leading to lymphocyte apoptosis of
TL carrying the Fas receptor (CD95). Since activated
TL express CD95, this mechanism might be partly re-
ponsible for the high CD81 lymphocyte apoptosis seen
in our untreated animals. In the treated monkeys, the
early reduction of viral load probably mimicked the lower
pathogenic potential of nef-defective, attenuated SIV, en-
abling the development of an antiviral immune response.
Kuroda et al. (1999) found a high percentage of AnnexinV-
binding cells in Mamu-A*01/p11C tetramer1 CD81 T cells
at the time of maximum CTL expansion early after infec-
tion of macaques with SIV. These data confirm our find-
ings that early loss of virus-specific CTL is detrimental
for the further development of a virus-specific immune
response.
Thus, the peak of CD81 cell apoptosis observed at 2
and 4 weeks after infection in untreated animals could
be the result of activation-induced cell death (AICD), to
eliminate much of the highly activated and potentially
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228 SPRING ET AL.cytopathic CTL after the initial expansion of this cell
population (Welsh et al., 1997). On the other hand, as
described above, it could also be directly virus-induced
apoptosis of SIV-specific CTL at the time of initial strong
viral replication in the peripheral blood.
CD41 T cells are essential for the development and
aintenance of CD81 T-cell effector responses (Matlou-
bian et al., 1994; Rosenberg et al., 1997, 1998; Zajac et al.,
1998). In one out of five monkeys we detected SIV-
specific proliferating lymphocytes early after withdrawal
of PMPA (Mm9045), whereas the other treated monkeys
exhibited proliferative activity later. Presumably, with a
more sensitive, flow cytometry-based technique we
would have detected the low T-cell activity in all animals
already present early after the infection (Pitcher et al.,
1999). However, proliferative activity was initially de-
tected in all macaques at several time points, clearly
indicating an improvement of the cellular immune re-
sponse of all animals. At 52 weeks after infection, when
no proliferation could be detected in the peripheral blood
of any monkey, high reactivity was readily detected in the
lymph nodes of the animals with lower viral load, but not
in the two macaques progressing to AIDS. This indicates
that the proliferative activity was only occasionally unde-
tectable by the assay in the periphery of the animals with
low viral load, likely as a result of low antigenic stimulus.
In contrast, T-cell proliferation could not be detected in
either blood or lymph nodes of the two macaques with
highest viral loads and was therefore definitely lost in
these monkeys.
T
Percentage CD41 and CD81 Lymphocyte Apoptosis in Untr
Lymphocyte
apoptosis
Weeks after
infection
Untreated macaques
Mm1863 Mm1895 Mm1907
D41 cells 0 1.4 1.3 1.6
1 1.4 1.8 2.7
2 1.2 0.6 1.1
4 1.9 0.8 2.4
8a 2.5 0.9 1.8
12 0.3 0.2 0.6
20 —b —b 0.2
CD81 cells 0 1.1 0.6 1.6
1 0.8 0.7 2.8
2 2.9c 4.7 6.6
4 7.5 5.5 10.5
8a 1.8 2.7 5.2
12 2.0 1.3 3.8
20 —b —b 0.6
a The PMPA-treated macaques were measured at Week 7 instead o
b Animals Mm1863 and Mm1895 rapidly progressed to AIDS and had
AIDS-related immunopathological disease.
c Percentage apoptosis twice the preinfection value was consideredNumerous studies previously demonstrated that ma-
caques immunized with live-attenuated SIV resist intra-venous and mucosal infection with pathogenic SIV
strains (e.g., Daniel et al., 1992; Stahl-Hennig et al., 1996;
Cranage et al., 1997; Johnson et al., 1999). In these
studies protection against challenge was associated
with the generation of proliferative T-helper responses by
the vaccine virus (Dittmer et al., 1995; Stahl-Hennig et al.,
1996). Recently, immunization with live-attenuated simian
immunodeficiency virus was found to induce a strong
type 1 T-helper response (Gauduin et al., 1999). Thus,
induction of a protective immunity appears to depend on
a strong virus-specific T-helper-cell response required
for the development of neutralizing antibodies and strong
CTL responses. The early chemotherapeutic treatment
applied here also induced virus-specific T-helper-cell
responses in all animals for a period of time, indepen-
dently of the viral load. However, only two macaques with
a persistent CD4 cell response in lymphoid organs were
able to control the viral replication efficiently for over 1
year. Evaluation of the number of CD29bright1-expressing
T-helper cells revealed that these cells decreased in the
three monkeys with higher viral loads. Similar results
were described by others after HIV or SIV infection
(Schnittman et al., 1990; Mattapallil et al., 1999; Sopper et
l., 2000; Leblond et al., 2000). CD29bright1 T-helper cells
belong to the memory subset and have strong helper-
inducer function. Through their b1-integrin expression,
CD29bright1 cells have a high capacity to migrate out of the
peripheral blood into the tissues (Leblond et al., 2000).
Thus, we speculate that, in these monkeys, more T-
helper cells moved out of the blood and more virus was
and PMPA-Treated SIVmac239-Infected Rhesus Macaques
PMPA-treated macaques
774 Mm9025 Mm9045 Mm9040 Mm9027 Mm9043
0.4 0.5 0.7 0.5 0.7
0.5 0.3 0.5 0.2 0.5
0.1 0.5 0.4 0.1 0.9
0.3 0.4 0.4 0.3 0.5
0.2 0.3 0.2 0.1 0.3
0.0 0.0 0.0 0.1 0.1
0.1 0.1 0.2 0.1 0.0
1.2 0.8 0.8 0.7 0.9
1.1 1.1 1.2 0.8 0.9
0.4 1.5 0.8 0.5 1.0
1.3 1.3 1.1 0.9 0.6
0.5 0.8 0.7 0.6 0.4
0.1 0.1 0.0 0.1 0.1
1.1 1.0 1.0 1.0 1.5
8 after infection.
erminated after 19 and 15 weeks, respectively, because of untreatable
e. Such values are indicated in bold.ABLE 2
eated
Mm8
0.9
0.3
0.1
1.3
0.2
0.1
0.3
1.2
0.9
1.1
6
2.5
3.3
0.5
f Week
to be ttargeted to the tissues, leading to the earlier loss of
proliferative activity in the peripheral blood and to high
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229IMMUNE RESPONSE OF SIV-INFECTED MACAQUES AFTER ARTvirus distribution. In contrast, the number of CD29bright1
T-helper cells remained stable in the two monkeys con-
trolling the viral replication, indicating a preservation of
their peripheral T-cell pool.
We did not detect high levels of apoptotic CD41 cells
either in the treated macaques with higher viral load or in
the untreated and infected monkeys, suggesting that the
decline in CD4 cells was at least partly induced by
mechanisms other than direct virus-induced apoptosis.
The loss of CD41 lymphocytes in the peripheral blood
might partly be the result of the above-proposed mech-
anism of T-helper-cell migration to extravascular tissues.
Since we applied antiviral therapy early in the
course of infection, presumably before the majority of
the virus-specific and most competent effector T cells
were lost, two animals were able to develop an effec-
tive immune response. It has yet to be evaluated
whether structured treatment interruption or a longer
treatment period could enhance the antiviral immune
response and lead to long-term nonprogression in
more animals. Our data confirm the finding of Rosen-
berg and colleagues (2000) that antiretroviral treat-
ment of HIV-infected individuals immediately after rec-
ognition of infection is important for a better progno-
sis. However, early treatment in combination with
effective vaccination during and after therapy should
induce a stronger immune response in more individ-
uals. Therapeutic vaccination in both acute and
chronic infection should be investigated in the future.
MATERIALS AND METHODS
Animals, infecting virus, and antiretroviral treatment
Five rhesus macaques (Macaca mulatta) of Indian
rigin (ranging from 3.6 to 4.1 kg) were allocated to the
tudy. They were seronegative for SIV, STLV-1, and D-type
irus. All five animals were inoculated intravenously with
00 median monkey infectious doses (MID50) of the
athogenic SIVmac239 (Lewis et al., 1994). For antiretro-
iral chemotherapy we used 9-[2-(R)-(phosphonome-
hoxy)propyl]adenine (PMPA, Tenofovir) generously pro-
ided by Gilead Sciences (Foster City, CA). The PMPA
as suspended in distilled water, dissolved by addition
f NaOH to a final pH of 7.0 at 60 mg/ml, and sterile
iltered (0.2 mm). Every morning, from Day 7 after infec-
tion, the animals received subcutaneously 30 mg PMPA
per kilogram of body weight. After 4 weeks the treatment
was stopped and the animals were monitored for the
development of a cellular immune response and their
ability to control the virus replication without treatment.
Lymphocyte phenotyping and counting
Phenotyping of lymphocytes was performed by flow
cytometry (EPICS XL flow cytometer; Coulter Electronics,
Krefeld, Germany) with peripheral blood mononuclearcells (PBMC) isolated by Ficoll–Hypaque density-gradi-
ent centrifugation. For triple-color staining 5 3 105 cells
were incubated in 50 ml RPMI 1640 medium with the
appropriate volumes of monoclonal antibodies in 5-ml
polystrene round-bottom tubes at room temperature for
20 min in the dark. Two different antibody combinations
were used to detect T-helper cells (CD3-FITC/CD4-PE/
CD8-TC) and memory T-helper cells (CD3-FITC/CD4-PE/
CD29-TC). The detection parameters were optimized for
every analysis protocol before measuring the samples
longitudinally. Appropriate isotype controls were per-
formed for all antibodies used. The following antibodies
were used: CD3-FITC (FN-18; Biosource International,
Camarillo, CA), CD4-PE (OKT-4; Ortho Diagnostics Sys-
tems, Raritan, NJ), CD8-TC (3B5; Caltag, South San Fran-
cisco, CA), and CD29-TC (4B4; Coulter Immunotech,
Krefeld, Germany). The CD29 antibody recognizes the
CD29 subunit of the b1-integrin very late activation anti-
gen-4 (VLA-4) and, therefore, detects lymphocytes with a
memory phenotype (Leblond et al., 2000). To determine
the absolute numbers of CD41 T cells and memory
T-helper cells in the blood, we gated on lymphocytes or
T cells within a lymphocyte gate and multiplied the per-
centages of CD31CD41 cells or CD31CD41CD29bright1
cells by the absolute number of lymphocytes obtained by
automated white blood cell counting.
Determination of lymphocyte apoptosis by AnnexinV
staining
The percentage of apoptotic CD41 and CD81 lympho-
ytes freshly isolated from the peripheral blood of the
nimals was investigated by AnnexinV staining in com-
ination with anti-CD4 and anti-CD8 antibodies. Annex-
nV is a member of the calcium and phospholipid binding
roteins and has high affinity for phosphatidylserine (PS)
n the presence of physiological concentrations of cal-
ium. Normally, PS is found only on the inner side of the
ell membrane and cannot be bound by AnnexinV. How-
ver, in the early phases of apoptosis cells exhibit an
ncreasing loss of cell membrane asymmetry, during
hich PS appears on the outer membrane and can be
etected by FITC-coupled AnnexinV. PBMC (5 3 105)
were suspended in 100 ml of RPMI 1640 medium, incu-
bated with the appropriate amounts of anti-CD4-PE and
anti-CD8-TC monoclonal antibody, and kept in the dark at
4°C for 20 min. After the incubation the cells were
washed and centrifuged at 300 g for 5 min. The lympho-
ytes were then suspended in 500 ml of ice-cold Annex-
inV-binding buffer and stained with 5 ml of FITC-labeled
AnnexinV (AnnexinV FITC-Apoptosis Detection Kit;
Coulter Immunotech). Analysis was performed after a
15-min incubation period. To establish the flow cytomet-
ric adjustments for the detection of AnnexinV-positive
cells with higher amounts of dead cells, we used lym-
phocytes after 1 day of in vitro cultivation. The antibody
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230 SPRING ET AL.combination AnnexinV-FITC/CD4-PE/CD8-TC was used
to detect the percentage of apoptotic CD41 and CD81
lymphocytes in freshly isolated PBMC. To control for the
amount of apoptotic versus necrotic cells in fresh PBMC
for each analysis, an additional sample of cells was
treated as described but anti-CD4 and anti-CD8 antibod-
ies were not added. Instead, the lymphocytes were
stained with AnnexinV and propidium iodine (PJ) after
resuspension in AnnexinV-binding buffer. In this assay,
apoptotic cells are AnnexinV positive but PJ negative,
whereas necrotic cells are both AnnexinV and PJ posi-
tive. We found all preparations of freshly isolated PBMC
containing less than 1% necrotic lymphocytes, resulting
from the preparation procedure. For analysis of our anti-
CD4 and anti-CD8 stained samples, percentages of ap-
optosis were considered positive when they were twice
the preinfection value.
Cell-associated and RNA-bound viral load in plasma
and lymph node sections
The viral load in plasma samples was determined by
quantitative RNA-PCR as described (Ten Haaft et al.,
1998). The cell-associated virus load in the peripheral
blood and lymph nodes was determined by a limiting
dilution cocultivation assay as described (Stahl-Hennig
et al., 1992, 1996). Determination of viral load in lymph
node sections was performed by in situ hybridization as
escribed (Stahl-Hennig et al., 1999). For the determina-
ion of the viral load and lymphoproliferative responses
n lymph node cells, the animals were sedated and
ymph nodes were removed from the axillar region. Lym-
hocytes were obtained by forcing the lymph node
hrough commercial nylon sieves (Stahl-Hennig et al.,
999).
etermination of cellular immune response
Cellular immune responses were analyzed by T-cell
roliferation assays in 96-well round-bottom plates.
or the 6-day proliferation assay, 5 3 104 PBMC per
well were stimulated with 2.5 mg/ml purified heat-
inactivated SIVmac251, 32H, or 10 mg/ml keyhole lim-
pet hemocyanine (KLH) as recall antigens. [3H]Thymi-
dine (0.2 mCi per well) was present during the last 18 h
of culture and the incorporated radioactivity was de-
termined in a b-counter (Microbeta-Workstation; Wal-
lac, Turku, Finland). A stimulation index (SI) was cal-
culated from the mean counts per minute of triplicate
wells by dividing the mean of antigen-containing cul-
tures by the mean of cultures without antigen. Accord-
ing to three preinfection measurements, SI . 3 were
onsidered positive. The proliferating cells in this as-
ay are CD4-positive and MHC class II restricted (Ditt-
er et al., 1994; Rosenberg et al., 1997). DStatistics
Data on lymphocyte apoptosis were analyzed with
Statistica software (version 989; StatSoft, Tulsa, OK) by
two-way ANOVA statistics.
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